The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

The European Medicines Agency (EMA) has started a review into the screening of patients before they begin treatment with certain drugs. Most of the drugs in question are chemotherapies, and they ...

Impact of targeted education on adverse drug reaction documentation in cancer center sites. This is an ASCO Meeting Abstract from the 2023 ASCO Quality Care Symposium. This abstract does not include a ...

Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says an EU panel.

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...